Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, facioscapulohumeral muscular dystrophy, facioscapulohumeral muscular dystrophy 1, facioscapulohumeral muscular dystrophy 2, frontometaphyseal dysplasia 2, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease, progressive muscular dystrophy	Active, not recruiting	Phase 2	2026-07-14		NCT06547216

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Avidity Biosciences, Inc.	6

17 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Duke University	Durham	United States	45
Kansas University Medical Center	Kansas City	United States	3
Ohio State University	Columbus	United States	19
Rare Disease Research	Atlanta	United States	12
Stanford University	Palo Alto	United States	161
University College London	London	United Kingdom	1
University of California Los Angeles	Los Angeles	United States	87
University of California San Diego	San Diego	United States	22
University of Colorado	Denver	United States	14
University of Florida	Gainesville	United States	70
University of Ottawa	Ottawa	Canada	1
University of Pennsylvania	Philadelphia	United States	507
University of Rochester Medical Center	Rochester	United States	162
University of Sheffield	Sheffield	United Kingdom	2
University of Texas Southwestern	Dallas	United States	73
University of Washington	Seattle	United States	31
Virginia Commonwealth University	Richmond	United States	156